Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Structure Therapeutics Inc. American Depositary Shares(GPCR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GPCR
10/16/2026: GPCR (2-star) is currently NOT-A-BUY. Pass it for now.
Structure Therapeutics is a clinical-stage biotechnology company that uses a proprietary platform to develop oral small-molecule drugs for metabolic and cardiovascular diseases. Its core strength lies in its ability to target G-protein-coupled receptors orally, potentially offering a more convenient alternative to injectable therapies. The primary investment story centers on the success of its lead candidate, GSBR-1290, which competes in the high-growth weight-loss market. Risks are significant, including intense competition from major pharmaceutical firms and the inherent dangers of clinical-stage development. This stock is best suited for growth-oriented investors with a high risk tolerance who are closely monitoring upcoming clinical trial readouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is a pure-play clinical-stage biotech with potential for high returns if clinical trials succeed. |
| Momentum investor | Strong fit while signal remains positive | Stock price often reacts sharply to clinical trial updates and data readouts in the metabolic space. |
| Value investor | Weak fit | The company lacks current earnings, revenue, or assets that would satisfy traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on high-risk drug development. |
| Low-risk investor | Weak fit | High clinical, regulatory, and market volatility make this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechs often experience wild price swings based on data readouts. |
| Valuation risk | Medium / high | Valuations are speculative and depend heavily on future clinical success. |
| Competition risk (GLP-1 metabolic competition) | High | Major incumbents like Novo Nordisk and Eli Lilly have vast resources to defend their market share. |
| Business quality | Medium | The company relies on its proprietary platform, which is innovative but unproven at commercial scale. |
| Dividend income | Low / none | No capital is returned to shareholders via dividends. |
| Execution risk | High | The company must successfully navigate complex clinical trials and regulatory approval processes. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 65.5% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/16/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.50B USD | Price to earnings Ratio - | 1Y Target Price 105.78 |
Price to earnings Ratio - | 1Y Target Price 105.78 | ||
Volume (30-day avg) 1.5M shares | Beta -1.37 | 52 Weeks Range 20.73 - 94.90 | Updated Date 10/16/2026 |
52 Weeks Range 20.73 - 94.90 | Updated Date 10/16/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.03 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development (R&D) | Clinical trial development for candidates like GSBR-1290 and ANPA-0073. | This is a pre-revenue company that relies on investor capital to fund future, potentially blockbuster, drug discoveries. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.23B | Price to Sales(TTM) - |
Enterprise Value 1.23B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -13.46 | Shares Outstanding 71.31M | Shares Floating 55.46M |
Shares Outstanding 71.31M | Shares Floating 55.46M | ||
Percent Insiders 3.11 | Percent Institutions 97.67 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.